{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T20:48:56Z","timestamp":1762375736565},"reference-count":38,"publisher":"Spandidos Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.3892\/or.2013.2588","type":"journal-article","created":{"date-parts":[[2013,7,4]],"date-time":"2013-07-04T09:21:48Z","timestamp":1372929708000},"page":"1081-1086","source":"Crossref","is-referenced-by-count":13,"title":["Cetuximab promotes anticancer drug toxicity in rhabdomyosarcomas with EGFR amplification in vitro"],"prefix":"10.3892","volume":"30","author":[{"given":"YUKI","family":"YAMAMOTO","sequence":"first","affiliation":[]},{"given":"KAZUMASA","family":"FUKUDA","sequence":"additional","affiliation":[]},{"given":"YASUSHI","family":"FUCHIMOTO","sequence":"additional","affiliation":[]},{"given":"YUMI","family":"MATSUZAKI","sequence":"additional","affiliation":[]},{"given":"YOSHIRO","family":"SAIKAWA","sequence":"additional","affiliation":[]},{"given":"YUKO","family":"KITAGAWA","sequence":"additional","affiliation":[]},{"given":"YASUHIDE","family":"MORIKAWA","sequence":"additional","affiliation":[]},{"given":"TATSUO","family":"KURODA","sequence":"additional","affiliation":[]}],"member":"2249","published-online":{"date-parts":[[2013,7,4]]},"reference":[{"key":"key20180107223115_b1-or-30-03-1081","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1136\/adc.88.4.354","article-title":"Update on childhood rhabdomyosarcoma","volume":"88","author":"McDowell","year":"2003","journal-title":"Arch Dis Child"},{"key":"key20180107223115_b2-or-30-03-1081","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1200\/JCO.1995.13.8.2123","article-title":"Biology and therapy of pediatric rhabdomyosarcoma","volume":"13","author":"Pappo","year":"1995","journal-title":"J Clin Oncol"},{"key":"key20180107223115_b3-or-30-03-1081","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1200\/JCO.1999.17.11.3468","article-title":"Indications for radiotherapy and chemotherapy after complete resection in rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Studies I to III","volume":"17","author":"Wolden","year":"1999","journal-title":"J Clin Oncol"},{"key":"key20180107223115_b4-or-30-03-1081","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2165\/00128072-200204010-00003","article-title":"Soft tissue sarcoma in children: prognosis and management","volume":"4","author":"Koscielniak","year":"2002","journal-title":"Paediatr Drugs"},{"key":"key20180107223115_b5-or-30-03-1081","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3322\/caac.20003","article-title":"Novel agents on the horizon for cancer therapy","volume":"59","author":"Ma","year":"2009","journal-title":"CA Cancer J Clin"},{"key":"key20180107223115_b6-or-30-03-1081","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.ctrv.2009.02.001","article-title":"Anti-epidermal growth factor receptor monoclonal antibodies in cancer treatment","volume":"35","author":"Capdevila","year":"2009","journal-title":"Cancer Treat Rev"},{"key":"key20180107223115_b7-or-30-03-1081","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJMoa033025","article-title":"Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer","volume":"351","author":"Cunningham","year":"2004","journal-title":"N Engl J Med"},{"key":"key20180107223115_b8-or-30-03-1081","doi-asserted-by":"crossref","first-page":"5578","DOI":"10.1200\/JCO.2005.07.120","article-title":"Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck","volume":"23","author":"Herbst","year":"2005","journal-title":"J Clin Oncol"},{"key":"key20180107223115_b9-or-30-03-1081","first-page":"311","article-title":"Squamous cell carcinoma of the head and neck","volume":"7","author":"Vermorken","year":"2002","journal-title":"J BUON"},{"key":"key20180107223115_b10-or-30-03-1081","first-page":"3666","article-title":"Anti-epidermal growth factor receptor monoclonal antibody 225 up-regulates p27KIP1 and induces G1 arrest in prostatic cancer cell line DU145","volume":"56","author":"Peng","year":"1996","journal-title":"Cancer Res"},{"key":"key20180107223115_b11-or-30-03-1081","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1172\/JCI117871","article-title":"Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin","volume":"95","author":"Wu","year":"1995","journal-title":"J Clin Invest"},{"key":"key20180107223115_b12-or-30-03-1081","first-page":"257","article-title":"Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice","volume":"5","author":"Perrotte","year":"1999","journal-title":"Clin Cancer Res"},{"key":"key20180107223115_b13-or-30-03-1081","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1038\/sj.onc.1204277","article-title":"Fibroblast growth factor and insulin-like growth factor differentially modulate the apoptosis and G1 arrest induced by anti-epidermal growth factor receptor monoclonal antibody","volume":"20","author":"Liu","year":"2001","journal-title":"Oncogene"},{"key":"key20180107223115_b14-or-30-03-1081","first-page":"909","article-title":"Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225","volume":"5","author":"Ciardiello","year":"1999","journal-title":"Clin Cancer Res"},{"key":"key20180107223115_b15-or-30-03-1081","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1002\/ijc.22370","article-title":"Cetuximab induce antibody-dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma","volume":"120","author":"Kawaguchi","year":"2007","journal-title":"Int J Cancer"},{"key":"key20180107223115_b16-or-30-03-1081","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1111\/j.1349-7006.2007.00510.x","article-title":"Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor","volume":"98","author":"Kimura","year":"2007","journal-title":"Cancer Sci"},{"key":"key20180107223115_b17-or-30-03-1081","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1158\/1078-0432.CCR-06-1726","article-title":"Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines","volume":"13","author":"Kurai","year":"2007","journal-title":"Clin Cancer Res"},{"key":"key20180107223115_b18-or-30-03-1081","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/BF01518458","article-title":"Therapeutic potential of chimeric and murine anti-(epidermal growth factor receptor) antibodies in a metastasis model for human melanoma","volume":"37","author":"Naramura","year":"1993","journal-title":"Cancer Immunol Immunother"},{"key":"key20180107223115_b19-or-30-03-1081","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Chou","year":"1984","journal-title":"Adv Enzyme Regul"},{"key":"key20180107223115_b20-or-30-03-1081","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"key20180107223115_b21-or-30-03-1081","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1002\/cncr.20986","article-title":"Expression of epidermal growth factor receptor, ERBB2 and KIT in adult soft tissue sarcomas: a clinicopathologic study of 281 cases","volume":"103","author":"Sato","year":"2005","journal-title":"Cancer"},{"key":"key20180107223115_b22-or-30-03-1081","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1038\/modpathol.3800636","article-title":"Expression and genomic status of EGFR and ErbB-2 in alveolar and embryonal rhabdomyosarcoma","volume":"19","author":"Ganti","year":"2006","journal-title":"Mod Pathol"},{"key":"key20180107223115_b23-or-30-03-1081","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1038\/sj.onc.1203607","article-title":"Transcriptional modulation of the anti-apoptotic protein BCL-XL by the paired box transcription factors PAX3 and PAX3\/FKHR","volume":"19","author":"Margue","year":"2000","journal-title":"Oncogene"},{"key":"key20180107223115_b24-or-30-03-1081","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/path.2170","article-title":"Global gene expression profiling of PAX-FKHR fusion-positive alveolar and PAX-FKHR fusion-negative embryonal rhabdomyosarcomas","volume":"212","author":"La\u00e9","year":"2007","journal-title":"J Pathol"},{"key":"key20180107223115_b25-or-30-03-1081","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1038\/labinvest.3700125","article-title":"Inducible short-term and stable long-term cell culture systems reveal that the PAX3-FKHR fusion oncoprotein regulates CXCR4, PAX3, and PAX7 expression","volume":"84","author":"Tomescu","year":"2004","journal-title":"Lab Invest"},{"key":"key20180107223115_b26-or-30-03-1081","doi-asserted-by":"crossref","first-page":"4742","DOI":"10.1158\/0008-5472.CAN-05-4292","article-title":"Validation of Met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma","volume":"66","author":"Taulli","year":"2006","journal-title":"Cancer Res"},{"key":"key20180107223115_b27-or-30-03-1081","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/gcc.20554","article-title":"Identification of PAX3-FKHR-regulated genes differentially expressed between alveolar and embryonal rhabdomyosarcoma: focus on MYCN as a biologically relevant target","volume":"47","author":"Mercado","year":"2008","journal-title":"Genes Chromosomes Cancer"},{"key":"key20180107223115_b28-or-30-03-1081","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1200\/JCO.2005.11.078","article-title":"Relationship between MYCN copy number and expression in rhabdomyosarcomas and correlation with adverse prognosis in the alveolar subtype","volume":"23","author":"Williamson","year":"2005","journal-title":"J Clin Oncol"},{"key":"key20180107223115_b29-or-30-03-1081","doi-asserted-by":"crossref","first-page":"6550","DOI":"10.1038\/onc.2008.255","article-title":"PDGFR-A is a therapeutic target in alveolar rhabdomyosarcoma","volume":"27","author":"Taniguchi","year":"2008","journal-title":"Oncogene"},{"key":"key20180107223115_b30-or-30-03-1081","doi-asserted-by":"crossref","first-page":"550","DOI":"10.2353\/ajpath.2009.080631","article-title":"Molecular classification of rhabdomyosarcoma - genotypic and phenotypic determinants of diagnosis: a report from the Children\u2019s Oncology Group","volume":"174","author":"Davicioni","year":"2009","journal-title":"Am J Pathol"},{"key":"key20180107223115_b31-or-30-03-1081","doi-asserted-by":"crossref","first-page":"7267","DOI":"10.1038\/sj.onc.1210525","article-title":"Comparative expression profiling identifies an in vivo target gene signature with TFAP2B as a mediator of the survival function of PAX3\/FKHR","volume":"26","author":"Ebauer","year":"2007","journal-title":"Oncogene"},{"key":"key20180107223115_b32-or-30-03-1081","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/j.1349-7006.2008.00748.x","article-title":"Different expression profiles of Y-box-binding protein-1 and multidrug resistance-associated proteins between alveolar and embryonal rhabdomyosarcoma","volume":"99","author":"Oda","year":"2008","journal-title":"Cancer Sci"},{"key":"key20180107223115_b33-or-30-03-1081","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/CJI.0b013e3181c549b0","article-title":"Cetuximab promotes immunotoxicity against rhabdomyosarcoma in vitro","volume":"33","author":"Herrmann","year":"2010","journal-title":"J Immunother"},{"key":"key20180107223115_b34-or-30-03-1081","doi-asserted-by":"crossref","first-page":"3992","DOI":"10.1158\/0008-5472.CAN-06-0191","article-title":"KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer","volume":"66","author":"Li\u00e8vre","year":"2006","journal-title":"Cancer Res"},{"key":"key20180107223115_b35-or-30-03-1081","unstructured":"Wellcome Trust Sanger InstituteCatalogue of Somatic Mutations in Cancerhttp:\/\/www.sanger.ac.uk\/genetics\/CGP\/cosmic\/Accessed June 4, 2012"},{"key":"key20180107223115_b36-or-30-03-1081","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1002\/gcc.20322","article-title":"Mutations of the PTPN11 and RAS genes in rhabdomyosarcoma and pediatric hematological malignancies","volume":"45","author":"Chen","year":"2006","journal-title":"Genes Chromosomes Cancer"},{"key":"key20180107223115_b37-or-30-03-1081","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/ijc.10398","article-title":"Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF-kappaB and AP-1 activation and IL-8 and VEGF expression in human head and neck squamous cell carcinoma lines","volume":"99","author":"Bancroft","year":"2002","journal-title":"Int J Cancer"},{"issue":"Suppl 1","key":"key20180107223115_b38-or-30-03-1081","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2165\/00003495-200060001-00002","article-title":"Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy","volume":"60","author":"Raymond","year":"2000","journal-title":"Drugs"}],"container-title":["Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/or.2013.2588\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,7]],"date-time":"2018-01-07T22:40:53Z","timestamp":1515364853000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/or.2013.2588"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,4]]},"references-count":38,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2013,7,4]]},"published-print":{"date-parts":[[2013,9]]}},"alternative-id":["10.3892\/or.2013.2588"],"URL":"https:\/\/doi.org\/10.3892\/or.2013.2588","relation":{},"ISSN":["1021-335X","1791-2431"],"issn-type":[{"value":"1021-335X","type":"print"},{"value":"1791-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,4]]}}}